ADvantage Therapeutics Secures $2.5M NIH Grant to Advance Alzheimer’s Candidate AD04®

ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, announced it has been awarded a $2.5 mil...

September 30, 2025 | Tuesday | News
Lupin to Acquire VISUfarma from GHO Capital, Expanding Ophthalmology Footprint in Europe

Global pharma major Lupin Limited (Lupin), announced its wholly owned subsidiary, Nanomi B.V. ('Nanomi'), has signed a definitive agreement for the acquisi...

September 29, 2025 | Monday | News
Philips Unveils Next-Generation CT and Helium-Free MR Systems to Transform Precision and Sustainability in Radiation Therapy

New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term value Philips deb...

September 29, 2025 | Monday | News
AstraZeneca Launches AstraZeneca Direct to Expand Affordable Access to Medicines with Home Delivery

AstraZeneca announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access th...

September 29, 2025 | Monday | News
Trump Prescribes a 100% Tariff: Because Nothing Says “Affordable Healthcare” Like Doubling the Price of Pills

US President Donald Trump has announced a 100% import tariff on all branded or patented pharmaceutical products, effective 1 October. The steep duty will d...

September 28, 2025 | Sunday | Analysis
Swisslog Healthcare Achieves HITRUST Certification, Underscoring Commitment to Data Security and Compliance

Certification validates Swisslog Healthcare's dedication to protecting sensitive data and meeting rigorous industry standards Swisslog Healthcar...

September 26, 2025 | Friday | News
Eisai and Biogen Gain Australian Approval for LEQEMBI® in Early Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. announced that the Therapeutic Goods Administration (TGA) of Australia has approved LEQEMBI® (lecanemab), a humanized...

September 25, 2025 | Thursday | News
Sanofi Ventures Secures $625M Boost, Expanding Assets to $1.4B

The fund will remain focused on Sanofi's key areas of immunology, rare diseases, neurology, and vaccines, backing earlier-stage innovation and emerging...

September 25, 2025 | Thursday | News
Booking Health Expands Access to Stage 4 Cancer Treatment in Germany

Booking Health, a leading medical travel facilitator, has announced the expansion of its oncology services to improve international access to advanced st...

September 25, 2025 | Thursday | News
Ncardia Launches First iPSC-Derived Non-Human Primate Cardiomyocytes for Translational Cardiac Research

-Ncardia, a leader in stem cell–based solutions for drug discovery and safety assessment,  announced the launch of Ncyte® NHP-C vCardiomyo...

September 24, 2025 | Wednesday | News
Remedium Bio and Eli Lilly Enter Multi-Target Gene Therapy Collaboration in Type 2 Diabetes and Obesity

Lifespan Vision Ventures is pleased to announce that its portfolio company, Remedium Bio, Inc. ("Remedium"), has entered into a multi-target research and...

September 24, 2025 | Wednesday | News
Illumina Expands Global CDx Partnerships to Advance KRAS-Targeted Precision Oncology

Illumina Inc. (NASDAQ: ILMN) will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the T...

September 24, 2025 | Wednesday | News
Rise Therapeutics Expands Oral Dendritic Cell Modulator Program into Sjögren’s Disease Following Positive RA Clinical Data

Supported by recent clinical data from the first-ever clinical study of an oral dendritic cell (DC) modulator in rheumatoid arthritis (RA), Rise Therapeu...

September 24, 2025 | Wednesday | News
Angelini Pharma and South Korea’s Sovargen Sign Global Option Agreement for First-in-Class Brain Health Therapy SVG105

Angelini Pharma, part of the privately owned Angelini Industries, and Sovargen, a South-Korean biotechnology company, announced today that they signed an...

September 23, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close